glp-1 nutrition nestle Nestlé Health Science launches 1 Daily Support has zero grams of sugar Nestle targeting weightless customers who

An open-label, 40-week, phase III randomized trial comparing weekly tirzepatide and semaglutide in type 2 diabetes mellitus patients indicated that reductions in body weight were greater and statistically significant with tirzepatide than with semaglutide in the secondary endpoints

6, 7, Figure 1, and Figure 2)

This is one of the biggest misconceptions around GLP-1 medications

These findings suggest clinicians should be aware of the potential ocular complications associated with GLP-1 RA use and are encouraged to report any suspected adverse events to postmarketing pharmacovigilance systems to facilitate safety tracking and raise public awareness.